125 related articles for article (PubMed ID: 20049443)
21. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
[TBL] [Abstract][Full Text] [Related]
22. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Bello CL; Sherman L; Zhou J; Verkh L; Smeraglia J; Mount J; Klamerus KJ
Anticancer Drugs; 2006 Mar; 17(3):353-8. PubMed ID: 16520665
[TBL] [Abstract][Full Text] [Related]
23. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
24. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
[TBL] [Abstract][Full Text] [Related]
25. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
26. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
27. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
[TBL] [Abstract][Full Text] [Related]
28. Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
de Wit D; Gelderblom H; Sparreboom A; den Hartigh J; den Hollander M; König-Quartel JM; Hessing T; Guchelaar HJ; van Erp NP
Cancer Chemother Pharmacol; 2014 Jan; 73(1):87-96. PubMed ID: 24149944
[TBL] [Abstract][Full Text] [Related]
29. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Faivre S; Delbaldo C; Vera K; Robert C; Lozahic S; Lassau N; Bello C; Deprimo S; Brega N; Massimini G; Armand JP; Scigalla P; Raymond E
J Clin Oncol; 2006 Jan; 24(1):25-35. PubMed ID: 16314617
[TBL] [Abstract][Full Text] [Related]
30. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
Everson G; Lasseter KC; Anderson KE; Bauer LA; Carithens RL; Wilner KD; Johnson A; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):21S-26S. PubMed ID: 10771450
[TBL] [Abstract][Full Text] [Related]
32. An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
Li Y; Wang X; Liu L; Zhang C; Gomez D; Reyes J; Palmisano M; Zhou S
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):346-354. PubMed ID: 29746728
[TBL] [Abstract][Full Text] [Related]
33. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
[TBL] [Abstract][Full Text] [Related]
34. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
35. Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
de Wit D; van Erp NP; Khosravan R; Wiltshire R; Allred R; Demetri GD; Guchelaar HJ; Gelderblom H
BMC Cancer; 2014 Aug; 14():575. PubMed ID: 25102852
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
Marzin K; Kretschmar G; Luedtke D; Kraemer S; Kuelzer R; Schlenker-Herceg R; Schmid U; Schnell D; Dallinger C
J Clin Pharmacol; 2018 Mar; 58(3):357-363. PubMed ID: 29106740
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Samant TS; Yang S; Miller M; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1001-1009. PubMed ID: 33555033
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
